Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Obsessive-Compulsive Disorder | 14 | 2025 | 806 | 2.210 |
Why?
|
| Opioid-Related Disorders | 5 | 2024 | 287 | 1.140 |
Why?
|
| Neonatal Abstinence Syndrome | 2 | 2024 | 19 | 1.050 |
Why?
|
| Electronic Health Records | 4 | 2024 | 781 | 1.040 |
Why?
|
| Empyema | 1 | 2022 | 24 | 0.780 |
Why?
|
| Analgesics, Opioid | 5 | 2024 | 457 | 0.780 |
Why?
|
| Evoked Potentials | 1 | 2022 | 115 | 0.740 |
Why?
|
| Osteogenesis Imperfecta | 4 | 2025 | 167 | 0.730 |
Why?
|
| Algorithms | 3 | 2024 | 1638 | 0.710 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2025 | 823 | 0.710 |
Why?
|
| International Classification of Diseases | 2 | 2019 | 94 | 0.680 |
Why?
|
| Pneumococcal Infections | 1 | 2022 | 278 | 0.650 |
Why?
|
| Telemedicine | 2 | 2024 | 488 | 0.620 |
Why?
|
| Sodium Lactate | 1 | 2019 | 2 | 0.610 |
Why?
|
| Computer Communication Networks | 1 | 2019 | 17 | 0.600 |
Why?
|
| Comparative Effectiveness Research | 1 | 2019 | 72 | 0.580 |
Why?
|
| Panic Disorder | 1 | 2019 | 52 | 0.580 |
Why?
|
| Clinical Coding | 1 | 2018 | 16 | 0.570 |
Why?
|
| Electroencephalography | 1 | 2022 | 823 | 0.560 |
Why?
|
| Patient Discharge | 2 | 2020 | 495 | 0.560 |
Why?
|
| Carbon Dioxide | 1 | 2019 | 275 | 0.550 |
Why?
|
| Medical Records | 1 | 2018 | 180 | 0.540 |
Why?
|
| Patient-Centered Care | 2 | 2020 | 224 | 0.530 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 2239 | 0.500 |
Why?
|
| Mental Disorders | 1 | 2024 | 862 | 0.490 |
Why?
|
| Phenotype | 2 | 2024 | 4309 | 0.460 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2020 | 1357 | 0.370 |
Why?
|
| Pandemics | 4 | 2022 | 1141 | 0.360 |
Why?
|
| Tennessee | 3 | 2025 | 34 | 0.350 |
Why?
|
| Humans | 35 | 2025 | 127455 | 0.330 |
Why?
|
| Adult | 20 | 2025 | 30579 | 0.320 |
Why?
|
| Chronic Pain | 2 | 2024 | 154 | 0.300 |
Why?
|
| Aged | 10 | 2025 | 20494 | 0.290 |
Why?
|
| Middle Aged | 15 | 2025 | 27867 | 0.290 |
Why?
|
| United States | 8 | 2025 | 11399 | 0.280 |
Why?
|
| Young Adult | 10 | 2025 | 9703 | 0.270 |
Why?
|
| Adolescent | 11 | 2025 | 20154 | 0.260 |
Why?
|
| Psychometrics | 3 | 2025 | 655 | 0.260 |
Why?
|
| Culturally Competent Care | 2 | 2024 | 50 | 0.250 |
Why?
|
| Qualitative Research | 3 | 2025 | 659 | 0.250 |
Why?
|
| Medicaid | 2 | 2019 | 242 | 0.240 |
Why?
|
| Male | 20 | 2025 | 62861 | 0.240 |
Why?
|
| Female | 21 | 2025 | 68733 | 0.240 |
Why?
|
| Uncertainty | 2 | 2023 | 94 | 0.230 |
Why?
|
| Academic Performance | 1 | 2025 | 24 | 0.230 |
Why?
|
| Academic Success | 1 | 2025 | 22 | 0.230 |
Why?
|
| Reproducibility of Results | 5 | 2025 | 2893 | 0.230 |
Why?
|
| Consumer Health Information | 1 | 2025 | 28 | 0.220 |
Why?
|
| Adaptation, Psychological | 2 | 2025 | 428 | 0.220 |
Why?
|
| Reward | 1 | 2025 | 113 | 0.220 |
Why?
|
| Opiate Substitution Treatment | 1 | 2024 | 38 | 0.220 |
Why?
|
| Benchmarking | 1 | 2025 | 133 | 0.220 |
Why?
|
| Hospitalization | 3 | 2024 | 1880 | 0.220 |
Why?
|
| Reproductive Health | 1 | 2024 | 47 | 0.210 |
Why?
|
| Self Report | 2 | 2024 | 538 | 0.210 |
Why?
|
| Gender Identity | 1 | 2024 | 73 | 0.210 |
Why?
|
| Interview, Psychological | 1 | 2024 | 103 | 0.210 |
Why?
|
| Evidence-Based Practice | 1 | 2024 | 110 | 0.210 |
Why?
|
| Buprenorphine | 1 | 2024 | 107 | 0.200 |
Why?
|
| Video Recording | 1 | 2025 | 200 | 0.200 |
Why?
|
| Incidence | 2 | 2022 | 3263 | 0.200 |
Why?
|
| Students | 1 | 2025 | 248 | 0.200 |
Why?
|
| Retrospective Studies | 8 | 2025 | 17076 | 0.200 |
Why?
|
| Anticipation, Psychological | 1 | 2022 | 6 | 0.200 |
Why?
|
| Resilience, Psychological | 1 | 2024 | 77 | 0.200 |
Why?
|
| Implosive Therapy | 1 | 2024 | 97 | 0.190 |
Why?
|
| Family | 1 | 2025 | 580 | 0.180 |
Why?
|
| Pain Management | 1 | 2024 | 196 | 0.180 |
Why?
|
| Radiosurgery | 1 | 2023 | 124 | 0.180 |
Why?
|
| Depressive Disorder | 1 | 2025 | 462 | 0.180 |
Why?
|
| Anemia, Sickle Cell | 1 | 2025 | 325 | 0.180 |
Why?
|
| Pneumococcal Vaccines | 1 | 2022 | 174 | 0.170 |
Why?
|
| Electrophysiology | 1 | 2021 | 252 | 0.170 |
Why?
|
| Fractures, Bone | 1 | 2023 | 193 | 0.170 |
Why?
|
| Aged, 80 and over | 4 | 2025 | 6716 | 0.170 |
Why?
|
| Psychotherapy | 1 | 2024 | 241 | 0.170 |
Why?
|
| Autistic Disorder | 1 | 2024 | 362 | 0.170 |
Why?
|
| Referral and Consultation | 1 | 2024 | 562 | 0.160 |
Why?
|
| Caregivers | 1 | 2025 | 562 | 0.150 |
Why?
|
| Hyperlipidemias | 1 | 2020 | 181 | 0.150 |
Why?
|
| Morphine | 1 | 2019 | 78 | 0.150 |
Why?
|
| Autism Spectrum Disorder | 1 | 2024 | 422 | 0.150 |
Why?
|
| Fentanyl | 1 | 2019 | 53 | 0.150 |
Why?
|
| Methadone | 1 | 2019 | 126 | 0.150 |
Why?
|
| Information Storage and Retrieval | 1 | 2019 | 61 | 0.140 |
Why?
|
| Administration, Inhalation | 1 | 2019 | 187 | 0.140 |
Why?
|
| Quality Improvement | 1 | 2024 | 684 | 0.140 |
Why?
|
| Anxiety Disorders | 1 | 2024 | 696 | 0.140 |
Why?
|
| Infusions, Intravenous | 1 | 2019 | 537 | 0.140 |
Why?
|
| Pregnancy | 3 | 2024 | 7423 | 0.130 |
Why?
|
| Severity of Illness Index | 4 | 2025 | 2999 | 0.130 |
Why?
|
| Hypoglycemic Agents | 1 | 2020 | 456 | 0.130 |
Why?
|
| Child | 7 | 2025 | 25296 | 0.120 |
Why?
|
| Depression | 1 | 2025 | 1295 | 0.120 |
Why?
|
| Genomics | 1 | 2023 | 1548 | 0.120 |
Why?
|
| Quality of Life | 1 | 2025 | 2030 | 0.120 |
Why?
|
| Immunosuppressive Agents | 1 | 2019 | 654 | 0.110 |
Why?
|
| Infant, Newborn | 2 | 2024 | 8368 | 0.110 |
Why?
|
| Latin America | 2 | 2024 | 95 | 0.100 |
Why?
|
| Meningitis, Fungal | 1 | 2012 | 3 | 0.100 |
Why?
|
| Interviews as Topic | 2 | 2025 | 424 | 0.100 |
Why?
|
| Drug Contamination | 1 | 2012 | 36 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2023 | 12580 | 0.090 |
Why?
|
| Methylprednisolone | 1 | 2012 | 93 | 0.090 |
Why?
|
| Hypertension | 1 | 2020 | 1335 | 0.090 |
Why?
|
| Prospective Studies | 1 | 2022 | 6249 | 0.090 |
Why?
|
| Disease Outbreaks | 1 | 2012 | 308 | 0.080 |
Why?
|
| Infant | 2 | 2023 | 12806 | 0.080 |
Why?
|
| Glucocorticoids | 1 | 2012 | 337 | 0.080 |
Why?
|
| Cohort Studies | 1 | 2019 | 4987 | 0.080 |
Why?
|
| Spain | 1 | 2025 | 60 | 0.060 |
Why?
|
| Risk Factors | 1 | 2019 | 10631 | 0.060 |
Why?
|
| Data Accuracy | 1 | 2024 | 30 | 0.050 |
Why?
|
| Factor Analysis, Statistical | 1 | 2025 | 233 | 0.050 |
Why?
|
| Transgender Persons | 1 | 2024 | 66 | 0.050 |
Why?
|
| Schools | 1 | 2025 | 235 | 0.050 |
Why?
|
| ROC Curve | 1 | 2025 | 592 | 0.050 |
Why?
|
| Self Efficacy | 1 | 2024 | 198 | 0.050 |
Why?
|
| Cultural Competency | 1 | 2024 | 51 | 0.050 |
Why?
|
| Urban Population | 1 | 2024 | 276 | 0.050 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2024 | 227 | 0.050 |
Why?
|
| Social Support | 1 | 2025 | 368 | 0.050 |
Why?
|
| Rural Population | 1 | 2024 | 247 | 0.050 |
Why?
|
| Infant Mortality | 1 | 2023 | 176 | 0.050 |
Why?
|
| Fear | 1 | 2023 | 201 | 0.050 |
Why?
|
| Ventral Striatum | 1 | 2021 | 27 | 0.050 |
Why?
|
| Electrodes | 1 | 2021 | 79 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2024 | 330 | 0.040 |
Why?
|
| Psychiatry | 1 | 2024 | 269 | 0.040 |
Why?
|
| Sulfonylurea Compounds | 1 | 2020 | 19 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 1438 | 0.040 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2020 | 31 | 0.040 |
Why?
|
| Mothers | 1 | 2023 | 363 | 0.040 |
Why?
|
| Thiazolidinediones | 1 | 2020 | 79 | 0.040 |
Why?
|
| Inpatients | 1 | 2024 | 540 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 227 | 0.040 |
Why?
|
| Cognition | 1 | 2024 | 806 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2021 | 799 | 0.040 |
Why?
|
| Metformin | 1 | 2020 | 159 | 0.040 |
Why?
|
| Length of Stay | 1 | 2024 | 1378 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2024 | 1274 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 1148 | 0.030 |
Why?
|
| Parents | 1 | 2024 | 1077 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2023 | 1730 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2025 | 5160 | 0.030 |
Why?
|
| Prognosis | 1 | 2025 | 4803 | 0.030 |
Why?
|
| Insulin | 1 | 2020 | 1128 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 1563 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 756 | 0.030 |
Why?
|
| Infectious Disease Incubation Period | 1 | 2012 | 7 | 0.020 |
Why?
|
| Aspergillus fumigatus | 1 | 2012 | 43 | 0.020 |
Why?
|
| Drug Compounding | 1 | 2012 | 39 | 0.020 |
Why?
|
| Ascomycota | 1 | 2012 | 27 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2023 | 3269 | 0.020 |
Why?
|
| Injections, Spinal | 1 | 2012 | 129 | 0.020 |
Why?
|
| Biomarkers | 1 | 2021 | 3252 | 0.020 |
Why?
|
| Public Health | 1 | 2012 | 270 | 0.020 |
Why?
|
| Antifungal Agents | 1 | 2012 | 296 | 0.020 |
Why?
|
| Stroke | 1 | 2012 | 1030 | 0.010 |
Why?
|